Founded in 1999, Avita Medical Limited (NASDAQ: RCEL) is headquartered in Cambridge, England, and is headquartered in Valencia, California. It has 87 full-time employees. It is a company operating as a regenerative medicine company in the Asia-Pacific region, Europe, the Middle East, Africa and the Americas .
Avita Medical Limited (RCEL):
Avita Medical is a clinical and commercial company that develops and markets a series of respiratory and regenerative products. Avita Medical Limited provides regenerative products to meet unmet medical needs in burns, trauma, chronic wounds, and dermatological and aesthetic indications.
Avita Medical’s patented and proprietary platform technology can provide treatment solutions derived from the patient’s own skin regeneration characteristics. Avita Medical’s main product is the RECELL System, which enables healthcare professionals to use a small sample of the patient’s own skin to produce a spray-on skin cell suspension (Spray-On Skin) for the treatment of adult patients over the age of 18 Acute thermal burns.
Avita Medical’s first regenerative medicine product on the market is ReCell skin spray, which is used to treat burns. The two latest products are ReNovaCell, for cosmetic and sculpting applications (including skin trauma), and ReGenerCell, for treating chronic wounds. The Avita Medical regenerative product line is currently sold in EMEA countries (Europe, Middle East and Africa) and Australia.
Avita Medical Limited (RCEL) History:
- On September 28, 2017, Avita Medical announced the submission of the US FDA Pre-Market Approval (PMA) application for the ReCell device for burn treatment.
- In October 2017, Avita Medical began raising US$17 million in funding for the ReCell Spray-On Skin product. The company cooperated with the Biomedical Advanced Research and Development Agency (BARDA) to raise funds to commercialize the product in the US market.
- On February 12, 2018, AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients treated with the FDA Compassionate Use Investigational Device Exemption (IDE) ReCell autologous cell collection device in the United States.
- On September 20, 2018, Avita Medical’s ReCell wound care device was approved by the FDA PMA.